Chronic Lymphocytic Leukemia (CLL) is a type of blood cancer that starts in the cells that become white blood cells in the bone marrow. CLL Extended 3 is a comprehensive diagnostic test that combines Flow Cytometry (FCM), Karyotyping, and Fluorescence In Situ Hybridization (FISH) to deeply analyze the cells affected by CLL. Flow Cytometry examines the physical and chemical properties of cells, Karyotyping looks at the number and structure of an individual's chromosomes, and FISH detects specific DNA sequences, including the 17p deletion, ATM deletion (11q), and Trisomy 12. By understanding the genetic characteristics of leukemia cells, doctors can assess the severity and make more informed treatment decisions.
The 17p deletion, ATM deletion, and Trisomy 12 are notable as they are associated with different forms and prognoses of CLL. Identifying these genetic markers can provide crucial information for tailored treatment plans.
Test NameCLL Extended 3: FCM CLL Panel and Karyotyping and FISH For 17p, ATM Del, and Trisomy 12
Sample TypeBlood/bone marrow
Preparations RequiredNo fasting is required. Inform your doctor of any medications or supplements you are taking.
Report Time12 days
What does CLL Extended 3 test entail?
CLL Extended 3 test involves the use of Flow Cytometry for cell characterization, Karyotyping for chromosome analysis, and FISH for detecting specific DNA sequences, including the 17p deletion, ATM deletion, and Trisomy 12, which are critical markers in CLL.
Why is the 17p deletion, ATM deletion, and Trisomy 12 significant in CLL?
The 17p deletion and ATM deletion are linked to a more aggressive form of CLL and poorer response to standard chemotherapy. Trisomy 12 is an additional chromosome that can also affect the course of CLL. Knowing the presence of these markers helps doctors to establish a more customized treatment plan.
Home Sample Collection Process
1
Book your convenient slot
2
Sample Collection by Phlebotomist
3
Reporting of the sample at lab
4
Download Reports
Frequently Asked Questions
If you have been diagnosed with CLL, this test provides detailed information on the genetic makeup of the leukemia cells, which can influence treatment options and management strategies.
No special preparation is needed. However, you should inform your doctor about any medications or supplements you are currently taking.
CLL Extended 3 provides comprehensive information about the properties and genetic characteristics of CLL cells, including chromosomal abnormalities like the 17p deletion, ATM deletion, and Trisomy 12.
Identifying chromosomal abnormalities such as the 17p and ATM deletions and Trisomy 12 may indicate that the disease is more aggressive or resistant to certain treatments. This information allows doctors to devise a more effective treatment plan tailored to your condition.
In a normal sample, the 17p and ATM deletions and Trisomy 12 should not be present. Their presence in CLL cells indicates chromosomal abnormalities.
If your test results are abnormal, it is essential to consult a hematologist or oncologist who specializes in blood cancers.
The levels detected can be influenced by the progression of CLL, previous treatments, and other chromosomal abnormalities.
There are no known ways to prevent chromosomal abnormalities in CLL. However, monitoring and early detection through tests like CLL Extended 3 can facilitate timely and targeted treatment.
Your doctor will decide the frequency of this test based on your condition and treatment plan.
While lifestyle changes such as a balanced diet and regular exercise are beneficial for general health, they are unlikely to impact the chromosomal abnormalities in CLL significantly.
Yes, you can undergo this test if you are pregnant or breastfeeding, but make sure to inform your doctor.
CLL Extended 3 is highly reliable in providing detailed genetic information about your CLL. However, CLL is a complex disease, and other factors should also be considered in determining the course and treatment.
CLL Extended 3 test is an important diagnostic tool that provides comprehensive information on the genetic characteristics of cells in Chronic Lymphocytic Leukemia. By detecting chromosomal abnormalities like the 17p deletion, ATM deletion, and Trisomy 12, this test aids in understanding the aggressiveness of the disease and helps in formulating a more tailored treatment plan. Regular consultations with a hematologist or oncologist, alongside appropriate treatment and monitoring, are essential in managing CLL effectively. This test is a critical component in the diagnostic and treatment pathway for individuals with CLL.
CLL Extended 3 (FCM CLL Panel and Karyotyping and FISH For 17p and ATM Del and Trisomy 12)
